Natera
NTRA
395.56
-5.09
-1.27%
Natera
US · NTRA
#387 by market cap
Listed 2015
395.56
-5.09
-1.27%
Live - 5344 symbols - heartbeat 60s ago
· 2026-10-08 07:00
Pre-market
392.49
-0.78%
After-hours
397.00
+0.36%
Overnight
394.41
-0.29%
- Market cap
- 57.02B
- P/E (TTM)i
- -293.01
- P/Bi
- 31.30
- EPSi
- -1.52
- Div yieldi
- 0.00%
- 52W posi
- 84%
Reader sentiment
Are you bullish or bearish on NTRA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.8 percentage points.
Institutional ownership
- Held by institutions
- 96.53% -0.83pp
- Institutions
- 1,025 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund70.03%
Hedge Fund13.81%
Public Company4.45%
Individual/Insider2.75%
Family Office/Trust2.33%
VC/PE Fund1.51%
Private Company1.42%
Government Pension Fund1.40%
Sovereign Wealth Fund1.33%
Other0.97%
Top holders
BlackRock
7.57%
J.P. Morgan Asset Management, Inc.
7.24%
T. Rowe Price Group, Inc.
7.04%
Vanguard Capital Management, LLC
4.96%
Vanguard Portfolio Management, LLC
4.01%
FMR
3.74%
Wellington Management Group
2.80%
State Street Global Advisors
2.54%
Duquesne Family Office LLC
2.21%
Geode Capital Management, LLC
1.91%
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Matthew Rabinowitz | Co-Founder & Executive Chairperson | 1.42% |
| Roelof Botha | Lead Independent Director | 0.75% |
| Jonathan Sheena | Co-Founder | 0.16% |
| John Fesko | President & Chief Business Officer | 0.11% |
| Daniel Rabinowitz | Secretary & Chief Legal Officer | 0.10% |
| Solomon Moshkevich | President of Clinical Diagnostics | 0.08% |
| Steven Chapman | Chief Executive Officer | 0.07% |
| James Healy | Independent Director | 0.03% |
| Roy Baynes | Independent Director | 0.01% |
| Michael Brophy | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Solomon Moshkevich | President of Clinical Diagnostics | Automatic Disposition | -3,000 | $411.62–415.07 |
| 2026-09-30 | Steven Chapman | Chief Executive Officer | Automatic Disposition | -1,273 | $413.31 |
| 2026-09-22 | Jonathan Sheena | Co-Founder | Automatic Disposition | -18,064 | $385.10–390.53 |
| 2026-09-15 | Jonathan Sheena | Co-Founder | Automatic Disposition | -9,150 | $348.03–356.87 |
| 2026-09-15 | Solomon Moshkevich | President of Clinical Diagnostics | Other Disposition | -945 | -- |
| 2026-09-14 | Matthew Rabinowitz | Co-Founder & Executive Chairperson | Automatic Disposition | -102,000 | $328.09–351.25 |
| 2026-09-10 | Matthew Rabinowitz | Co-Founder & Executive Chairperson | Automatic Disposition | -50,000 | $325.01–329.62 |
| 2026-09-01 | Solomon Moshkevich | President of Clinical Diagnostics | Automatic Disposition | -18,160 | $319.76–326.89 |
| 2026-08-31 | Solomon Moshkevich | President of Clinical Diagnostics | Intent to Sell (Form 144) | -3,000 | $320.73 |
| 2026-08-31 | Steven Chapman | Chief Executive Officer | Automatic Disposition | -1,698 | $320.99 |
| 2026-08-09 | Jonathan Sheena | Co-Founder | Automatic Disposition | -6,000 | $325.32 |
| 2026-08-09 | John Fesko | President & Chief Business Officer | Automatic Disposition | -6,517 | $321.53 |
| 2026-08-06 | Matthew Rabinowitz | Co-Founder & Executive Chairperson | Automatic Disposition | -2,000 | $320.90 |
| 2026-08-06 | Jonathan Sheena | Co-Founder | Automatic Disposition | -9,150 | $308.40–320.90 |
| 2026-08-05 | John Fesko | President & Chief Business Officer | Other Acquisition | +20,000 | -- |
| 2026-08-03 | Michael Brophy | Chief Financial Officer | Automatic Disposition | -795 | $267.99–274.22 |
| 2026-08-03 | Michael Brophy | Chief Financial Officer | Intent to Sell (Form 144) | -478 | $270.36 |
| 2026-08-02 | Matthew Rabinowitz | Co-Founder & Executive Chairperson | Automatic Disposition | -731 | $267.99 |
| 2026-08-02 | Jonathan Sheena | Co-Founder | Automatic Disposition | -109 | $267.99 |
| 2026-08-02 | Solomon Moshkevich | President of Clinical Diagnostics | Automatic Disposition | -3,410 | $259.98–268.70 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.